TRHC · Tabula Rasa Healthcare, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $299.52M | $331.26M | $297.22M | $284.71M | $94.79M | $134.55M |
| Cost of Revenue | $232.60M | $233.36M | $204.81M | $181.35M | $137.67M | $65.18M |
| Gross Profit | $66.91M | $97.90M | $92.41M | $103.35M | ($42.88M) | $69.37M |
| R&D | $14.48M | $19.79M | $18.18M | $21.74M | $12.22M | $5.63M |
| SG&A | $74.97M | $73.76M | $65.38M | $50.90M | $28.18M | $21.18M |
| Total Operating Expenses | $135.89M | $167.22M | $157.80M | $136.00M | $116.34M | $35.69M |
| D&A | - | - | - | - | - | - |
| Operating Income | ($68.97M) | ($69.32M) | ($65.39M) | ($32.65M) | ($49.74M) | $5.20M |
| Interest Expense | - | $9.11M | $20.74M | $15.99M | $906.0K | $688.0K |
| Income Tax | $389.0K | $627.0K | ($5.17M) | ($16.20M) | ($3.38M) | ($9.78M) |
| Net Income | ($147.51M) | ($79.06M) | ($80.97M) | ($32.44M) | ($47.27M) | $14.30M |
| EPS - Basic | ($6.07) | ($3.71) | - | ($1.57) | ($2.48) | $0.85 |
| EPS - Diluted | ($6.07) | ($3.71) | - | ($1.57) | ($2.48) | $0.76 |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $70.02M | $9.67M | $23.36M | $42.48M | $20.28M | $10.43M |
| Accounts Receivable | $19.25M | $34.05M | $32.52M | $29.12M | $27.95M | $17.09M |
| Inventory | $6.57M | $5.44M | $4.26M | $3.70M | $3.59M | $2.79M |
| Accounts Payable | $19.46M | $13.18M | $11.24M | $8.62M | $14.83M | $16.22M |
| Current Assets | $170.26M | $89.89M | $93.21M | $94.54M | $63.31M | $33.61M |
| Total Assets | $384.15M | $499.42M | $514.44M | $492.39M | $270.96M | $185.99M |
| Current Liabilities | $102.08M | $73.92M | $72.22M | $40.00M | $75.73M | $27.77M |
| Long-term Debt | - | - | - | $226.29M | - | - |
| Total Liabilities | $441.18M | $443.66M | $345.91M | $306.84M | $131.95M | $63.50M |
| Stockholders' Equity | ($57.03M) | $55.76M | $168.53M | $185.55M | $139.01M | $122.49M |
| Retained Earnings | ($407.86M) | ($260.35M) | ($179.90M) | ($98.93M) | ($66.50M) | ($20.63M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.36M | $15.45M | $4.82M | ($5.82M) | $15.83M | $6.77M |
| Investing Cash Flow | $91.30M | ($35.19M) | ($28.73M) | ($180.93M) | ($43.81M) | ($10.90M) |
| Financing Cash Flow | ($31.96M) | $6.92M | $5.87M | $208.29M | $42.58M | $6.44M |
| CapEx | $2.29M | $3.35M | $3.09M | $7.47M | $4.99M | $3.30M |
| Free Cash Flow | $5.07M | $12.10M | $1.73M | ($13.29M) | $10.84M | $3.47M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 22.3% | 29.6% | 31.1% | 36.3% | -45.2% | 51.6% |
| Operating margin | -23.0% | -20.9% | -22.0% | -11.5% | -52.5% | 3.9% |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | -49.2% | -23.9% | -27.2% | -11.4% | -49.9% | 10.6% |
| Free cash flow margin | 1.7% | 3.7% | 0.6% | -4.7% | 11.4% | 2.6% |
| FCF / Net income | -0.03 | -0.15 | -0.02 | 0.41 | -0.23 | 0.24 |
| R&D / Revenue | 4.8% | 6.0% | 6.1% | 7.6% | 12.9% | 4.2% |
| SG&A / Revenue | 25.0% | 22.3% | 22.0% | 17.9% | 29.7% | 15.7% |
| Effective tax rate | - | - | - | - | - | -216.8% |
| Return on assets | -38.4% | -15.8% | -15.7% | -6.6% | -17.4% | 7.7% |
| Return on equity | 258.6% | -141.8% | -48.0% | -17.5% | -34.0% | 11.7% |
| Return on invested capital | - | - | - | -6.3% | - | - |
| Liquidity | ||||||
| Current ratio | 1.67 | 1.22 | 1.29 | 2.36 | 0.84 | 1.21 |
| Quick ratio | 1.60 | 1.14 | 1.23 | 2.27 | 0.79 | 1.11 |
| Cash ratio | 0.69 | 0.13 | 0.32 | 1.06 | 0.27 | 0.38 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 1.22 | - | - |
| Debt / Assets | - | - | - | 0.46 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -7.6x | -3.2x | -2.0x | -54.9x | 7.6x |
| Equity multiplier | -6.74 | 8.96 | 3.05 | 2.65 | 1.95 | 1.52 |
| Liabilities / Assets | 1.15 | 0.89 | 0.67 | 0.62 | 0.49 | 0.34 |
| Efficiency | ||||||
| Asset turnover | 0.78 | 0.66 | 0.58 | 0.58 | 0.35 | 0.72 |
| Inventory turnover | 35.43 | 42.86 | 48.07 | 49.01 | 38.31 | 23.32 |
| Days sales outstanding | 23d | 38d | 40d | 37d | 108d | 46d |
| Days inventory outstanding | 10d | 9d | 8d | 7d | 10d | 16d |
| Days payable outstanding | 31d | 21d | 20d | 17d | 39d | 91d |
| Cash conversion cycle | 3d | 25d | 27d | 27d | 78d | -29d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -9.6% | 11.5% | 4.4% | 200.4% | -29.5% | 43.0% |
| Revenue CAGR (3y) | 1.7% | 51.8% | 30.2% | 44.7% | - | - |
| Revenue CAGR (5y) | 17.4% | 28.6% | - | - | - | - |
| Gross profit growth (YoY) | -31.7% | 5.9% | -10.6% | - | - | 140.2% |
| Operating income growth (YoY) | 0.5% | -6.0% | -100.3% | 34.4% | - | 14.3% |
| Net income growth (YoY) | -86.6% | 2.4% | -149.6% | 31.4% | - | - |
| EPS growth (YoY) | -63.6% | - | - | 36.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -58.1% | 600.8% | - | - | 212.4% | 17.2% |
| FCF CAGR (5y) | 7.9% | 32.5% | - | - | - | - |
| Book value growth (YoY) | - | -66.9% | -9.2% | 33.5% | 13.5% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$331.26M totalCarevention Healthcare$248.01M · 74.9%
Medwise Healthcare$83.25M · 25.1%
Product / service
$662.04M totalProduct$190.07M · 28.7%
Pace Product$189.59M · 28.6%
Service$141.19M · 21.3%
Pace Solutions$58.42M · 8.8%
Software Subscription And Services$44.27M · 6.7%
Medication Safety Services$38.50M · 5.8%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-0.61
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Business Services, NEC
Comparing Tabula Rasa HealthCare against the 5 most active filers in the same SIC group.